Form 4: Boston Scientific Director Receives Equity Awards

Christophe Pierre Weber, a Director at Boston Scientific Corp., reported the acquisition of restricted stock and deferred stock units valued at approximately $465,500.

Summary

• Director Christophe Pierre Weber acquired restricted stock and deferred stock units on May 7, 2026.
• The acquisition includes restricted stock granted in lieu of 80% of yearly cash compensation, valued at approximately $100,000.
• An annual equity award in the form of restricted stock, valued at $64,500, was also acquired.
• Additionally, deferred stock units valued at $150,500 were received as part of an annual equity award.
• These awards are set to vest in full upon the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details director compensation through equity awards rather than providing operational or financial performance updates.

Positives

• Director Weber received significant equity awards, indicating continued investment in the company's future.
• The awards are structured to vest upon the next annual meeting, aligning director incentives with near-term company performance.
• The total value of equity awards received is substantial, reflecting a portion of the director's compensation package.

Negatives

• The filing details compensation rather than operational or financial performance, offering no direct insight into the company's current business health.

Risks

• The value of the restricted stock and deferred stock units is subject to the fluctuation of Boston Scientific's common stock price.
• Vesting is contingent on the director remaining in their role until the next annual meeting.

Future Outlook

The awards are structured to vest in full upon the next annual meeting of stockholders, indicating a near-term outlook for the director's continued service and alignment with company performance.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice in the medical technology industry to attract and retain talent and align executive interests with shareholder value. The structure of these awards, vesting upon the next annual meeting, is typical for non-employee director compensation.

Stakeholder Impact

• Shareholders: The equity awards align director incentives with shareholder interests, potentially leading to decisions that enhance shareholder value. The value of these awards is tied to the company's stock performance.
• Employees: While not directly impacting employees, the compensation structure for directors reflects the company's overall approach to executive and board compensation.
• Management: The awards are part of the compensation package for the reporting person, Christophe Pierre Weber, as a Director.

Next Steps

• Vesting of restricted stock and deferred stock units upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Director Compensation, Equity Awards, Restricted Stock, Deferred Stock Units, SEC Filing, Insider Trading